CCND1 and hepatocellular carcinoma: We confirmed the effects of C504244 and Lenvatinib on HCC cells by checking the activation status of their target signaling pathways, including phosphorylation of VEGFR/Epidermal Growth Factor Receptor (EGFR) and expression of c-Myc and Cyclin D1.